Allogeneic hematopoietic stem cell transplantation could improve survival for pure CBF-AML patients with minimal residual disease positive after the second consolidation. Issue 4 (21st March 2021)

• Record Type: Journal Article
• Authors: Wang, Tanzhen; Zhou, Biqi; Zhang, Jubin; Zhang, Xinyue; Liu, Tianhui; Qiu, Huiying; Sun, Aining; Chen, Suning; Wu, Depei; Xu, Yang
• Is Part Of: Leukemia & lymphoma. Volume 62:Issue 4(2021)
• Page Start: 995
• Page End: 998
• Publication Date: 2021-03-21
• Subjects: Core binding factor acute myeloid leukemia -- allogeneic hematopoietic stem cell transplantation -- minimal residual disease -- clinical outcomes -- prognostic factors; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2020.1846736
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: The role of MRD-directed risk stratification strategy for core binding factor acute myeloid leukemia (CBF-AML) patients with favorable risk genetics is still unknown. We retrospectively analyzed the clinical outcomes of 148 pure CBF-AML patients with first complete remission including MRD positive ( n = 69) and MRD negative ( n = 79) after two courses of consolidation from January 2009 to December 2018 in our center. We found that MRD positive after 2 courses of consolidation significantly influenced OS (5-year: 59%), PFS (5-year: 36%) and CIR (5-year: 58%) in favorable-risk CBF-AML patients with CR1. It was worth noting that the MRD status after two courses of consolidation might be the best timing for treatment choice and allo-HSCT was a promising treatment for favorable-risk CBF-AML patients with MRD positive after the second consolidation.